|
|
|
|
|
by pkaye
3087 days ago
|
|
But this seems to be different situation from what the article is talking about which is the inadequate involvement of minorities in drug trials. You are highlighting the lack of adequate health coverage which is a different issue in the US. But this bring up a question if blacks and other minorities have the poorer health outcomes in other countries? Japan, China, South Korea for example does their own drug testing and development so would they find that a particular drug doesn't work on their population at all? What about the black population in UK or France? Do they also have poorer health outcomes? |
|
It seems a complex question that has many facets. Two tickets that come to mind:
1. When US sociologists and political scientists talk about “systemic and structural racism” this is one of the manifestations.
That in general the well being of Native peoples in the US, of African Americans is devalued. It is witnessed in the exclusion in drug trials, in the diseases that pharma considers worthwhile to address, in the staffing of hospitals, in the access to healthcare,etc.
2. The unique inefficiency of the US healthcare system among those of wealthy countries has been documented in depth so I don’t know if is possible to do an adequate comparison of progressive health systems (e.g. Japan, UK, Finland) against that of the US.
It might be worthwhile to pull in progressive health systems that focus primarily upon Black people —- Botswana comes to mind —- as a point of comparison.